Inside J&J’s Atraverse Medical Acquisition

Johnson & Johnson’s agreement to acquire Atraverse Medical fits a pattern that has become increasingly familiar across medtech M&A. Strategic buyers are continuing to target commercial-stage companies operating in expanding procedural markets where workflow advantages and ecosystem positioning matter just as much as the core technology itself.

This deal also highlights something else: the founders behind FARAPULSE have once again identified a procedural bottleneck inside the same operating room and built a company around solving it. Steven Mickelsen, John Slump, Eric Sauter, and their broader team previously helped reshape pulsed-field ablation before Boston Scientific acquired FARAPULSE in 2021. Now, they have built a left-heart access platform that Johnson & Johnson believes strengthens Biosense Webster’s position in EP.

The timing is important. So is the strategic fit.

J&J’s Structural Advantage in EP

Johnson & Johnson’s electrophysiology (EP) business is not simply large. It is deeply embedded in the clinical workflow through Biosense Webster and the CARTO mapping platform.

Today, Biosense Webster controls more than 40% of the U.S. EP ablation catheter market and roughly 60% globally. Much of that position is tied directly to the widespread adoption of CARTO, which has remained the leading cardiac mapping system for decades. More than 5,000 systems are now installed worldwide.

That installed base creates a powerful commercial foundation. Every new EP technology integrated into the Biosense Webster portfolio immediately benefits from existing physician familiarity, procedural integration, and access to established hospital infrastructure.

That is where HOTWIRE enters the picture.

Why Atraverse Medical Matters

Atraverse developed HOTWIRE to simplify transseptal access, a critical step in left-heart procedures used to treat atrial fibrillation and other arrhythmias. Physicians must cross from the right atrium into the left atrium before ablation can begin, making this one of the foundational steps in nearly every left-heart ablation procedure.

It is also one of the most technically sensitive portions of the workflow.

Conventional RF guidewires continuously deliver energy during septal crossing. Once the wire enters the left atrium, there is potential for unintended tissue injury. Existing approaches can also introduce procedural inefficiencies, including sheath exchanges, inconsistent crossing forces, and risk of dilator skiving and emboli creation.

HOTWIRE was designed specifically to address those issues. Its impedance-guided RF generator automatically stops energy delivery once left atrial entry is detected. It is currently the only device with that capability.

Clinical performance data have reinforced the value proposition. A multicenter first-in-human study involving roughly 500 patients demonstrated 100% procedural success. Data presented at the 2026 European Heart Rhythm Association meeting showed a 0% incidence of unintended left atrial injury, compared to rates exceeding 50% observed with other RF guidewires in comparative studies.

The workflow benefits are equally important:

• Zero-exchange functionality that acts as both the crossing tool and support rail
• Increased stiffness relative to competing systems for improved large-bore sheath support
• Universal sheath compatibility that avoids forcing physicians into new procedural workflows

These types of improvements matter in high-volume AFib programs where complication reduction, procedural efficiency, and downstream cost control directly affect operational performance.

Since receiving FDA 510(k) clearance in 2024, the device has already been used in approximately 3,000 procedures as part of a limited market release. The company achieved that traction with roughly $40 million in funding and in under four years of operation.

The Founders Keep Reappearing

One of the more interesting aspects of the acquisition is the recurring founder pattern emerging across EP.

The same team that built FARAPULSE has now developed a transseptal access system that directly competes with Boston Scientific’s own offering, while ultimately landing inside the portfolio of Boston Scientific’s largest EP competitor.

There is some irony in the fact that Boston Scientific’s ProTrack device served as the regulatory predicate for HOTWIRE.

More broadly, this reinforces how experienced procedural founders continue identifying unresolved workflow challenges in EP and building companies around them. That dynamic is now drawing attention toward other names in the category, including Field Medical, Volta Medical, Del Medtech, Pulse Bioscience, and Galvanize Therapeutics.

Some are focused on next-generation EP technologies. Others are extending pulsed-field energy into entirely new indications outside the heart.

None are guaranteed to follow the same trajectory, but the FARAPULSE-to-Atraverse sequence demonstrates how repeat founders with deep procedural expertise continue shaping the competitive landscape.

What the Deal Means for J&J

From a portfolio perspective, the logic behind the acquisition is straightforward.

HOTWIRE complements the Biosense Webster ecosystem by positioning J&J to offer physicians a more integrated procedural pathway from left-heart access through ablation. The technology fits naturally alongside VARIPULSE and CARTO within a unified EP platform.

The company’s Q1 2026 results suggest the broader strategy may already be gaining momentum. J&J’s EP business generated $1.49 billion during the quarter, representing 12.6% year-over-year growth. This represents a meaningful acceleration following a relatively flat stretch in early 2025 when competitive PFA pressure was at its height.

The addition of Atraverse Medical strengthens that momentum by adding a commercially validated access platform into an ecosystem that already dominates procedural mapping. As long as CARTO maintains its structural advantage, each tuck-in acquisition compounds the overall value of the Biosense Webster platform and further reinforces J&J’s position in the rapidly growing EP market.